ATE301462T1 - Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden - Google Patents

Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden

Info

Publication number
ATE301462T1
ATE301462T1 AT99916114T AT99916114T ATE301462T1 AT E301462 T1 ATE301462 T1 AT E301462T1 AT 99916114 T AT99916114 T AT 99916114T AT 99916114 T AT99916114 T AT 99916114T AT E301462 T1 ATE301462 T1 AT E301462T1
Authority
AT
Austria
Prior art keywords
disorders
reboxetine
addiction
neuropsychiatric conditions
treat neuropsychiatric
Prior art date
Application number
AT99916114T
Other languages
English (en)
Inventor
Fred Hassan
John Michael Mccall
Duncan Paul Taylor
Voigtlander Philip F Von
Erik Ho Fong Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE301462T1 publication Critical patent/ATE301462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99916114T 1998-04-09 1999-04-02 Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden ATE301462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123198P 1998-04-09 1998-04-09
PCT/US1999/004289 WO1999052531A1 (en) 1998-04-09 1999-04-02 New treatments for nervous disorders

Publications (1)

Publication Number Publication Date
ATE301462T1 true ATE301462T1 (de) 2005-08-15

Family

ID=22162900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916114T ATE301462T1 (de) 1998-04-09 1999-04-02 Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden

Country Status (24)

Country Link
US (1) US6352986B1 (de)
EP (1) EP1069900B1 (de)
JP (1) JP2002511414A (de)
KR (1) KR20010034758A (de)
CN (1) CN1301164A (de)
AT (1) ATE301462T1 (de)
AU (1) AU756373B2 (de)
BR (1) BR9909478A (de)
CA (2) CA2634698A1 (de)
CZ (1) CZ297346B6 (de)
DE (1) DE69926616T2 (de)
DK (1) DK1069900T3 (de)
EA (1) EA200001049A1 (de)
ES (1) ES2244189T3 (de)
HU (1) HUP0102436A3 (de)
IL (1) IL138855A0 (de)
NO (1) NO20005059L (de)
NZ (1) NZ507398A (de)
PL (1) PL193797B1 (de)
PT (1) PT1069900E (de)
SK (1) SK14492000A3 (de)
TR (1) TR200002868T2 (de)
WO (1) WO1999052531A1 (de)
ZA (1) ZA200004454B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ATE305788T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
SK12812002A3 (sk) * 2000-03-07 2003-08-05 Eli Lilly And Company Spôsob liečenia psoriázy
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1578422B1 (de) 2002-12-20 2007-04-11 NicoNovum AB Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
DE3275000D1 (en) * 1981-08-07 1987-02-12 Holset Engineering Co Impeller for centrifugal compressor
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IL122984A0 (en) * 1995-07-24 1998-08-16 Lilly Co Eli Treatment of attention-deficit/ hyperactivity disorder
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки

Also Published As

Publication number Publication date
WO1999052531A1 (en) 1999-10-21
KR20010034758A (ko) 2001-04-25
AU756373B2 (en) 2003-01-09
TR200002868T2 (tr) 2001-01-22
CN1301164A (zh) 2001-06-27
HUP0102436A2 (hu) 2001-11-28
DK1069900T3 (da) 2005-10-31
JP2002511414A (ja) 2002-04-16
PT1069900E (pt) 2005-10-31
EP1069900A1 (de) 2001-01-24
PL346293A1 (en) 2002-01-28
CA2321157A1 (en) 1999-10-21
CZ20003671A3 (en) 2001-06-13
ZA200004454B (en) 2002-04-24
PL193797B1 (pl) 2007-03-30
IL138855A0 (en) 2001-10-31
DE69926616D1 (de) 2005-09-15
AU3449499A (en) 1999-11-01
DE69926616T2 (de) 2006-05-24
BR9909478A (pt) 2000-12-19
EA200001049A1 (ru) 2001-04-23
CA2634698A1 (en) 1999-10-21
NZ507398A (en) 2004-01-30
NO20005059D0 (no) 2000-10-06
EP1069900B1 (de) 2005-08-10
US6352986B1 (en) 2002-03-05
ES2244189T3 (es) 2005-12-01
CZ297346B6 (cs) 2006-11-15
NO20005059L (no) 2000-10-06
HUP0102436A3 (en) 2002-01-28
SK14492000A3 (sk) 2001-06-11

Similar Documents

Publication Publication Date Title
MY127739A (en) Use of pramipexole for the treatment of addictive disorders
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TW200607510A (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
DE69926616D1 (de) Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE69305776D1 (de) Behandlung neurodegenerativer Krankheiten
NO20031019D0 (no) Vedvarende frigivelsesformuleringer av oksymorfon
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
NO20023486D0 (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE296098T1 (de) Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
EA200300271A1 (ru) Соединения для лечения расстройств, связанных с зависимостью
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
EA200001058A1 (ru) Новые способы лечения нервных расстройств
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
BR9914570A (pt) Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1069900

Country of ref document: EP

REN Ceased due to non-payment of the annual fee